Fundamental Analysis
ARIHANT CAPITAL MARKETS LTD.
Face Value : Rs5
BUY: Rs196.5
Ticker: 511605
H/L: Rs203.05/62
Equity: Rs10.41Cr
Arihant Capital service provider offering stock trading, commodity trading, currency derivatives trading, mutual funds, Demat account, insurance broking, wealth management, all at a great value. The company reported net sales of Rs 38.56 crore in Q2FY22 as compared to Rs 27.97 crore Q2FY21. The operating profit zoomed by 52.15 per cent i.e. to Rs 17.13 from Rs 11.26 crore in Q2FY21. The net profit also jumped to Rs 12.31 crore Rs 8.09 crore witnessing a 52.11 per cent increase. The company focuses on niche customer segments and had recorded strong net profit growth of 97 per cent in FY22. The growth is compelled by high tech usage which ensures optimization of operating cost, stable asset quality, normalizing credit cost, and high capital ratios. Hence, we recommend BUY.
AVADH SUGAR & ENERGY LTD
Face Value : Rs10
BUY: Rs460.80
Ticker: 540649
H/L: Rs548.55/172.7
Equity: Rs3.75Cr
Avadh Sugar & Energy Limited manufactures sugar and its products. The Company produces industrial alcohol, ethanol, and rectified spirits. Avadh Sugar & Energy owns and operates power generation plants. Analyzing the quarterly performance the company net sales stood at Rs 619.61 crore in Q2FY22 as compared Rs 619.93 crore in Q2FY21 giving a degrowth of 0.05 per cent. The operating profit came out to be Rs 76.30 crore a 39.8 percent surge as opposed to Rs 54.57 crore in Q2FY21. Net profit for the quarter ended stood at Rs 25.24 crore a significant increase from Rs 7.21 crore reported in Q2FY21. Due to the shortfall in production of sugar in other countries ethanol manufacturing and sugar exports, sugar prices have increased during the current quarter. The company's efficient improvement and profitability development have been led by way of, modernization and expansion of ethanol capacity. Hence, we recommend BUY.
JAGSONPAL PHARMACEUTICALS LTD.
Face Value : Rs5
BUY: Rs179.60
Ticker: 507789
H/L: Rs203.25/70
Equity: Rs13.10 Cr
Jagsonpal is one of the India's premier pharmaceutical companies. Jagsonpal has substantial research and development, manufacturing, marketing, and distribution facilities. In terms of quarterly consolidated performance, the company delivered net sales of Rs 59.49 crore in Q2FY22 which is higher than Rs 56.35 crore delivered in Q2FY21. Operating Profit stands at Rs 10.57 crore which is double than operating profit of Rs 5.25 crore in Q2FY21. The company reported an 82.38 per cent increase in Net Profit i.e. Rs 7.31 crore as compared to a net profit of Rs 4.01 crore in Q2FY21. The company’s performance has been quite good. The company has an impeccable track record of growth and profitability spanning over 4 decades. The company has an ROE of 20 per cent which is considered good. And it has also delivered impressive earnings growth. Hence, we recommend BUY.
MAN INFRACONSTRUCTION LTD.
Face Value : Rs2
BUY: Rs101.6
Ticker : 533169
H/L: Rs107.90/22.34
Equity : Rs49.50Cr
Man Infraconstruction is a leading construction company in India that has executed construction work for some of the most significant port projects in the country. On the consolidated quarterly front, the company recorded a significant increase in the net sales and operating income, which stood at Rs 247.34 crore for Q2FY22 as compared to the net sales & operating income of Rs 42.63 crore reported for Q2FY21. The quarter recorded an operating profit of Rs 253.30 crore in Q2FY22 as compared to the operating profit of Rs 19.88 crore posted in Q2FY21. The company reported a net profit of Rs 173.35 crore in Q2FY22 against the net loss of Rs 0.48 crore in Q2FY21. Recently, the company has incorporated a new subsidiary in the name of ‘MICL Estates LLP’, for carrying out the business of real estate and other related activities. Hence, owing to a positive bias towards the stock, we recommend BUY.
MPHASIS LTD.
Face Value : Rs10
BUY: Rs3347.15
Ticker: 526299
H/L: Rs3,659.75/1,399.30
Equity: Rs187.21Cr
Mphasis Limited is an Indian multinational information technology services & consulting company based in Bengaluru, India. Analysing the consolidated quarterly results, the company recorded an increase of 17.81 per cent in the net sales & operating income, which stood at Rs 2,869.23 crore for Q2FY22 as compared to the net sales and operating income of Rs 2,435.43 crore reported for Q2FY21. The operating profit for the quarter was recorded at Rs 541.93 crore in Q2FY22 as compared to the operating profit of Rs 478.54 crore posted in Q2FY21, a rise of 13.25 per cent. The company reported a net profit of Rs 341.4 crore in Q2FY22 versus Rs 299.23 crore recorded in Q2FY21, an improvement of 14.11 per cent. Healthy margins as well as management stability, improving the deal size, market share gains via vendor consolidation are likely to drive growth in direct revenues. Hence, we recommend BUY
TRANSPORT CORP. OF INDIA LTD.
Face Value : Rs2
BUY: Rs759.00
Ticker: 532349
H/L: Rs838/236.60
Equity: Rs15.46Cr
Transport Corporation of India (TCI) is a leading provider of integrated multimodal logistics and supply chain solutions. On a consolidated quarterly front, the company recorded an increase of 18.4 per cent in the net sales & operating income, which stood at Rs 107.43 crore for Q2FY22 as compared to the net sales and operating income of Rs 68.81 crore reported for Q2FY21. The operating profit zoomed 56.13 per cent, standing at Rs 107.43 crore in Q2FY22 as compared to the operating profit of Rs 68.81 crore recorded in Q2FY21. The company reported a net profit of Rs 68.88 crore in Q2FY22 as against the net profit of Rs 32.62 crore recorded in Q2FY21, ascending robustly. The company bears healthy expansion plans and intends to spend Rs 150 crore-Rs 200 crore in terms of Capex. The company has positive gain in terms of market share and is growing faster than the growth of the market. Hence, we recommend BUY